Novartis shares drop 10% after third drug trial setback

Novartis shares fell 10% after its muscular dystrophy drug candidate failed to meet efficacy endpoints, marking the third recent setback in its R&D pipeline. The failure raises uncertainty about the company's near-term growth prospects and may pressure its stock further. The market reaction reflects investor concern over pipeline value and future revenue streams.